CA3126822A1 - Combinaton therapy with a don prodrug and an immune checkpoint inhibitor - Google Patents

Combinaton therapy with a don prodrug and an immune checkpoint inhibitor Download PDF

Info

Publication number
CA3126822A1
CA3126822A1 CA3126822A CA3126822A CA3126822A1 CA 3126822 A1 CA3126822 A1 CA 3126822A1 CA 3126822 A CA3126822 A CA 3126822A CA 3126822 A CA3126822 A CA 3126822A CA 3126822 A1 CA3126822 A1 CA 3126822A1
Authority
CA
Canada
Prior art keywords
compound
diazo
acetamido
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3126822A
Other languages
English (en)
French (fr)
Inventor
Robert Christian WILD
Thomas Estok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dracen Pharmaceuticals Inc
Original Assignee
Dracen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dracen Pharmaceuticals Inc filed Critical Dracen Pharmaceuticals Inc
Publication of CA3126822A1 publication Critical patent/CA3126822A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3126822A 2019-01-18 2020-01-17 Combinaton therapy with a don prodrug and an immune checkpoint inhibitor Pending CA3126822A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962794231P 2019-01-18 2019-01-18
US62/794,231 2019-01-18
PCT/US2020/014149 WO2020150639A1 (en) 2019-01-18 2020-01-17 Combinaton therapy with a don prodrug and an immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
CA3126822A1 true CA3126822A1 (en) 2020-07-23

Family

ID=71614516

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3126822A Pending CA3126822A1 (en) 2019-01-18 2020-01-17 Combinaton therapy with a don prodrug and an immune checkpoint inhibitor

Country Status (13)

Country Link
US (1) US20220117938A1 (https=)
EP (1) EP3911310A4 (https=)
JP (1) JP7574198B2 (https=)
KR (1) KR20210117303A (https=)
CN (1) CN113438947A (https=)
AU (1) AU2020208637A1 (https=)
BR (1) BR112021014112A2 (https=)
CA (1) CA3126822A1 (https=)
EA (1) EA202191992A1 (https=)
IL (1) IL284907A (https=)
MX (1) MX2021008546A (https=)
SG (1) SG11202107317WA (https=)
WO (1) WO2020150639A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3153424A1 (en) * 2019-10-03 2021-04-08 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof
WO2022022612A1 (en) * 2020-07-29 2022-02-03 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
JP7846686B2 (ja) * 2020-10-02 2026-04-15 ドラセン ファーマシューティカルズ インコーポレイテッド 皮下投与のための（ｓ）－イソプロピル２－（（ｓ）－２－アセトアミド－３－（１ｈ－インドール－３－イル）プロパンアミド）－６－ジアゾ－５－オキソヘキサノエートを含む凍結乾燥組成物およびその使用
EP4229029B1 (en) * 2020-10-15 2026-02-25 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
CN114621120B (zh) * 2020-12-10 2023-11-03 深圳先进技术研究院 一种don前药分子、前药激活化合物和前药激活体系
US20240246902A1 (en) * 2021-04-29 2024-07-25 The Johns Hopkins University Prodrugs of 6-diazo-5-oxo-l-norleucine
WO2022261117A1 (en) * 2021-06-07 2022-12-15 Dracen Pharmaceuticals, Inc. Combination therapy with a don prodrug and a tigit inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
NZ718821A (en) 2013-09-11 2022-07-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors
EP3113798B1 (en) 2014-03-07 2019-06-05 University Health Network Methods and compositions for modifying the immune response
US20160113925A1 (en) * 2014-10-22 2016-04-28 Emory University Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors
CA2994165A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
EP3328374A4 (en) 2015-07-31 2019-03-13 The Johns Hopkins University GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
AU2016302940B2 (en) 2015-07-31 2021-02-04 The Johns Hopkins University Prodrugs of glutamine analogs
US20180244783A1 (en) * 2015-08-31 2018-08-30 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN110869765A (zh) * 2017-04-20 2020-03-06 Adc治疗有限公司 组合疗法
CN111566083A (zh) * 2017-10-06 2020-08-21 约翰·霍普金斯大学 新的谷氨酰胺拮抗剂及其用途

Also Published As

Publication number Publication date
EA202191992A1 (ru) 2021-12-17
JP2022518232A (ja) 2022-03-14
WO2020150639A1 (en) 2020-07-23
EP3911310A1 (en) 2021-11-24
CN113438947A (zh) 2021-09-24
BR112021014112A2 (pt) 2021-10-13
SG11202107317WA (en) 2021-08-30
US20220117938A1 (en) 2022-04-21
JP7574198B2 (ja) 2024-10-28
AU2020208637A1 (en) 2021-09-09
MX2021008546A (es) 2021-11-12
KR20210117303A (ko) 2021-09-28
IL284907A (en) 2021-09-30
EP3911310A4 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
US20220117938A1 (en) Combinaton therapy with a don prodrug and an immune checkpoint inhibitor
US20220304984A1 (en) Amino acid transport inhibitors and the uses thereof
US20220265590A1 (en) Dibenzylamines as amino acid transport inhibitors
AU2025242155A1 (en) Preservation of immune response during chemotherapy regimens
US20210269480A1 (en) Bicyclic peptide ligands specific for nectin-4
KR102491013B1 (ko) Tg02를 사용한 암의 치료
JP2021185195A (ja) Ｃｘｃｒ４阻害剤およびその使用
CA3144985A1 (en) Hdac6-activated macrophages, compositions, and uses thereof
US20210315909A1 (en) Polymorphic compounds and uses thereof
AU2023202746A1 (en) Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
CA3191515A1 (en) Stat-activated macrophages, compositions, and uses thereof
US20240174658A1 (en) Heteroaromatic Inhibitors of Cancer Metabolism
US20240246902A1 (en) Prodrugs of 6-diazo-5-oxo-l-norleucine
US20220332676A1 (en) Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof
US20160368980A1 (en) Inhibition of granulocyte colony stimulating factor in the treatment of cancer
TW202329962A (zh) 治療癌症之方法
WO2022261117A1 (en) Combination therapy with a don prodrug and a tigit inhibitor
US20230372294A1 (en) Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for subcutaneous administration and the use thereof
WO2016123733A1 (zh) 绿原酸在制备治疗卵黄囊瘤的药物中的用途